CNBC Pro

Piper Sandler downgrades Biogen as Alzheimer's drug hits another speedbump

A sign marks a Biogen facility, in Cambridge, Massachusetts, March 9, 2020.
Brian Snyder | Reuters

Piper Sandler on Wednesday downgraded Biogen after the biotechnology company faced another hiccup in the rollout of its Alzheimer's drug.

More In Street Calls

Here are Friday's biggest analyst calls: Apple, Tesla, McDonald's, Netflix, Carvana, Microsoft & more
CNBC ProHere are Friday's biggest analyst calls: Apple, Tesla, McDonald's, Netflix, Carvana, Microsoft & more
Cowen names Costco a best idea, says wholesaler can be a big winner in 2023
CNBC ProCowen names Costco a best idea, says wholesaler can be a big winner in 2023
Mizuho downgrades Coinbase, says stock could fall 30% if deal key to revenue is renegotiated
CNBC ProMizuho downgrades Coinbase, says stock could fall 30% if deal key to revenue is renegotiated